Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of PTGR1, PTPN14 and ASPH to identify patients who may benefit from treatment with LP-184.
Lantern said its RADR® artificial intelligence platform helped identify the biomarker signature used in the patent, supporting the development of a precision medicine approach for LP-184. The company reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial and plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio. The patent allowance is a critical step in protecting Lantern's proprietary approach to cancer treatment, potentially giving the company a competitive edge in the development of biomarker-driven therapies.
This news matters because it underscores the growing role of artificial intelligence in drug development. By leveraging its RADR platform, Lantern has identified a biomarker signature that could personalize treatment for several difficult-to-treat cancers. The three-gene signature—PTGR1, PTPN14, and ASPH—may allow physicians to select patients most likely to respond to LP-184, improving efficacy and reducing unnecessary side effects. The allowance also strengthens Lantern's intellectual property moat, which is crucial for a clinical-stage biotech company seeking to attract partnerships and investment.
For investors, the patent allowance signals progress in Lantern's pipeline and its strategic focus on precision oncology. The company's plan to initiate Phase 1b/2 studies in 2026 provides a clear near-term catalyst. Additionally, the commercialization of its AI platform, withZeta.ai, as a subscription-based research tool represents a new revenue stream that could reduce reliance on external funding. The full press release is available at https://ibn.fm/LRGUo.
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company's pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. With withZeta.ai now commercially available, Lantern is generating revenue from its AI capabilities while advancing its clinical programs.
